These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 15286899)
1. [The use of Xalacom and deterioration in cases of vitiligo. Is there a causal relationship?]. Arnalich-Montien F; Lara-Medina J; Muñoz-Negrete FJ; Rebolleda G Arch Soc Esp Oftalmol; 2004 Jul; 79(7):315-6. PubMed ID: 15286899 [No Abstract] [Full Text] [Related]
4. Objective vs. subjective factors in the psychological impact of vitiligo: the experience from a French referral centre. Kostopoulou P; Jouary T; Quintard B; Ezzedine K; Marques S; Boutchnei S; Taieb A Br J Dermatol; 2009 Jul; 161(1):128-33. PubMed ID: 19298280 [TBL] [Abstract][Full Text] [Related]
5. DLQI scores in vitiligo: reliability and validity of the Persian version. Aghaei S; Sodaifi M; Jafari P; Mazharinia N; Finlay AY BMC Dermatol; 2004 Aug; 4():8. PubMed ID: 15294022 [TBL] [Abstract][Full Text] [Related]
6. Profile of vitiligo in the south of Tunisia. Akrem J; Baroudi A; Aichi T; Houch F; Hamdaoui MH Int J Dermatol; 2008 Jul; 47(7):670-4. PubMed ID: 18613871 [TBL] [Abstract][Full Text] [Related]
7. Willingness-to-pay and quality of life in patients with vitiligo. Radtke MA; Schäfer I; Gajur A; Langenbruch A; Augustin M Br J Dermatol; 2009 Jul; 161(1):134-9. PubMed ID: 19298268 [TBL] [Abstract][Full Text] [Related]
9. Prediction of clinical response to excimer laser treatment in vitiligo by using neural network models. Cazzaniga S; Sassi F; Mercuri SR; Naldi L Dermatology; 2009; 219(2):133-7. PubMed ID: 19546510 [TBL] [Abstract][Full Text] [Related]
10. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. Esfandiarpour I; Ekhlasi A; Farajzadeh S; Shamsadini S J Dermatolog Treat; 2009; 20(1):14-8. PubMed ID: 18608735 [TBL] [Abstract][Full Text] [Related]
11. Association of interferon-gamma and tumor necrosis factor alpha polymorphisms with susceptibility to vitiligo in Iranian patients. Namian AM; Shahbaz S; Salmanpoor R; Namazi MR; Dehghani F; Kamali-Sarvestani E Arch Dermatol Res; 2009 Jan; 301(1):21-5. PubMed ID: 18820938 [TBL] [Abstract][Full Text] [Related]
12. A comparative study of oxidant-antioxidant status in stable and active vitiligo patients. Ines D; Sonia B; Riadh BM; Amel el G; Slaheddine M; Hamida T; Hamadi A; Basma H Arch Dermatol Res; 2006 Sep; 298(4):147-52. PubMed ID: 16897080 [TBL] [Abstract][Full Text] [Related]
13. Treatment of vitiligo with broadband ultraviolet B and vitamins. Don P; Iuga A; Dacko A; Hardick K Int J Dermatol; 2006 Jan; 45(1):63-5. PubMed ID: 16426381 [TBL] [Abstract][Full Text] [Related]
14. Camouflaging vitiligo of the fingers. Tanioka M; Miyachi Y Arch Dermatol; 2008 Jun; 144(6):809-10. PubMed ID: 18559781 [No Abstract] [Full Text] [Related]
15. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Passeron T; Ostovari N; Zakaria W; Fontas E; Larrouy JC; Lacour JP; Ortonne JP Arch Dermatol; 2004 Sep; 140(9):1065-9. PubMed ID: 15381545 [TBL] [Abstract][Full Text] [Related]
16. [Vitiligo as a lasting result of skin tests]. Holzegel K Dtsch Gesundheitsw; 1973 Jan; 28(3):133-6. PubMed ID: 4691918 [No Abstract] [Full Text] [Related]
17. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. Parsad D; Kanwar AJ; Kumar B J Eur Acad Dermatol Venereol; 2006 Feb; 20(2):175-7. PubMed ID: 16441626 [TBL] [Abstract][Full Text] [Related]